// App-Quantinova.ai

: Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.

Researchers

Presenter

  • Noel W. Clarke

Principal Investigators

  • Antoine Thiery-Vuillemin

  • Pawel J. Wiechno

  • Boris Alekseev

  • Nuria Sala

  • Robert Jones

  • Ivo Kocak

  • Vincenzo Emanuele Chiuri

  • Jacek Jassem

  • Aude Flechon

  • Charles Redfern

  • Carsten Dietrich Goessl

  • Joseph Burgents

  • Christopher Gresty

  • Arnold Degboe

  • Fred Saad

Medical Centers

  • The Christie and Salford Royal Hospitals, Manchester, United Kingdom

  • Uiniversity Hospital Minjoz, Besancon, France

  • Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

  • Hertzen Moscow Oncology Research Institute, Moscow, Russia

  • Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain

  • Velindre Cancer Centre and Cardiff University, Cardiff, United Kingdom

  • Masaryk Memorial Cancer Institute, Brno, Czech Republic

  • Ospedale 'Vito Fazzi', Lecce, Italy

  • Medical University of Gdansk, Gdansk, Poland

  • Centre Leon Berard, Lyon, France

  • Sharp HealthCare, San Diego, CA

  • AstraZeneca, Gaithersburg, MD

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

Locations

  • United Kingdom

  • France

  • Poland

  • Russia

  • Spain

  • Czech Republic

  • Italy

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Docetaxel

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT01972217

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved